✓ Translated by DotMD AI Clinical Council Source: World journal of urology • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #34002265 ↗

Phase III Randomized Trial: The HELENA study: Hexvix ® -TURB vs. white-light TURB followed by intravesical adjuvant chemotherapy-a prospective randomized controlled open-label multicenter non-inferiority study (N = 113)

Original Paper Title: “The HELENA study: Hexvix ® -TURB vs. white-light TURB followed by intravesical adjuvant chemotherapy-a prospective randomized controlled open-label multicenter non-inferiority study”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 113
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Non-inferiority of Hexvix ® TURB relative to white-light TURB with maintenance Mitomycin instillation in intermediate risk urothelial carcinoma of the bladder was not proven. Hence a higher effect of maintenance ICT is to assume compared to a Hexvix ® -improved TURB only, confirming its important role in patient treatment.
  • Study Design & Sample: Phase III Randomized Trial published in World journal of urology (N = 113 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in World journal of urology (2021), this phase iii randomized trial evaluating 113 human participants investigated: Photodynamic diagnosis and white-light TURB with adjuvant intravesical chemotherapy (ICT) is widely used in treatment of bladder cancer. Key clinical takeaway: Non-inferiority of Hexvix ® TURB relative to white-light TURB with maintenance Mitomycin instillation in intermediate risk urothelial carcinoma of the bladder was not proven. Hence a higher effect of maintenance ICT is to assume compared to a Hexvix ® -improved TURB only, confirming its important role in patient treatment.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (World journal of urology, 2021-10-15; N = 113; Rigor 82/100): Non-inferiority of Hexvix ® TURB relative to white-light TURB with maintenance Mitomycin instillation in intermediate risk urothelial carcinoma of the bladder was not proven. Hence a higher effect of maintenance ICT is to assume compared to a Hexvix ® -improved TURB only, confirming its important role in patient treatment.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: aminolevulinic-acid-hydrochloride → Rx: mitomycin → Rx: urinary-pain-relief-phenazopyridine-hydrochloride → Condition: carcinoma-metastatic → Condition: bladder-cancer →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 34002265: Phase III Randomized Trial: The HELENA study: Hexvix ® -TURB vs. white-light TURB followed by intravesical adjuvant chemotherapy-a prospective randomized controlled open-label multicenter non-inferiority study (N = 113)

3 of 3 Free Questions Remaining